Abstract IA15: T-Cells targeting mutated RAS—clinical trials

Durable complete regressions of metastatic cancers can be achieved by the transfer of in vitro expanded tumor-reactive T-cells. In patients with melanoma, this can be done by giving tumor-infiltrating lymphocytes (TIL) reactive with tumor-specific mutated antigens (“neoantigens”). Unfortunately, the vast majority of immunogenic neoantigens have been shown to be totally patient specific. One exception is that T cells recognizing mutated KRAS have...